Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
 - EconoTimes)
NEW YORK, April 14, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of SCYNEXIS, Inc. (NASDAQ:SCYX) who purchased shares (1) pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company’s Initial Public Offering on or about May 2, 2014 and/or (2) between May 2, 2014 and March 2, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey.
In particular complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) SCYNEXIS’s lead product SCY-078 posed substantial undisclosed health and safety risks; (ii) consequently, the Company had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result of the foregoing, SCYNEXIS’s public statements were materially false and misleading at all relevant times.
On March 2, 2017, SCYNEXIS announced that the U.S. Food and Drug Administration “informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data” of the formulation. The hold stems from “three mild-to-moderate thrombotic events in healthy volunteers” receiving the formulation.
Shareholders have until May 8, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/scynexis-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
